Inclusion Criteria:

          -  Patient has a histologically or cytologically confirmed diagnosis of ALK positive
             (ALK+) tumor other than Non-Small Cell Lung Cancer (NSCLC).

          -  Patient must provide an archival or fresh tumor tissue before the first dose of the
             study drug for ALK testing at a Novartis designated central laboratory.

          -  Patient has WHO Performance Status (PS) ≤ 2

          -  Patient must have received at least one line of prior systemic treatment for
             recurrent, locally advanced and/or metastatic disease, and may have discontinued for:

               -  Disease progression as defined by RECIST 1.1 for solid tumors; by RANO for GBM
                  and by Cheson assessment criteria for lymphoma, or

               -  Intolerance described as any discontinuation due to an AE of any grade despite
                  appropriate supportive treatment

          -  Patient has at least one measurable lesion as defined by appropriate guidelines. A
             lesion at a previously irradiated site may only be counted as a target lesion if there
             is clear sign of progression since the irradiation.

          -  Patient has received no chemotherapy, immunotherapy or stem cell therapy at least 4
             weeks before starting ceritinib

          -  Radiotherapy and prior ALK inhibitors must be stopped at least 1 week prior to
             starting ceritinib

          -  Recovered from all toxicities related to prior anticancer therapies to grade ≤ 1
             (Common Terminology Criteria for Adverse Events [CTCAE] v4.03).

        Exclusion Criteria:

          -  Patient has ALK+lung cancer

          -  Patient with symptomatic CNS metastases who are neurologically unstable or have
             required increasing doses of steroids within the 2 weeks prior to study entry to
             manage CNS symptoms.

          -  Patient with acute or chronic GI disease that may significantly alter the absorption
             of ceritinib.

          -  Patient with a history of pancreatitis or history of increased amylase or lipase that
             was due to pancreatic disease.

          -  Patient has history of interstitial lung disease or interstitial pneumonitis,
             including clinically significant radiation pneumonitis.

          -  Patient has clinically significant, uncontrolled heart disease and/or recent cardiac
             event (within 6 months).

          -  Patient has evidence of active viral hepatitis, including Hepatitis A, B or C (testing
             for viral hepatitis is not mandatory).

          -  Patient has known diagnosis of human immunodeficiency virus (HIV) infection (HIV
             testing is not mandatory).